CARBOPLATIN-PACLITAXEL INDUCED ACUTE MULTI-VESSEL CORONARY THROMBOSIS
Journal of the American College of Cardiology
; 79(9):2659, 2022.
Article
in English
| EMBASE | ID: covidwho-1768647
ABSTRACT
Background:
Delayed cancer screenings during COVID-19 pandemic are expected to increase use of chemotherapy agents like paclitaxel. Paclitaxel has been implicated in rare cases of acute myocardial infarction from chemotoxicity. We present a rare case and literature review of Paclitaxel-induced acute multiple vessel coronary thrombosis in absence of native coronary artery atherosclerosis. Case A 68-year-old man with a history of metastatic stage IV non-small cell lung cancer, hypertension, hyperlipidemia, normal baseline left ventricular systolic function and without coronary disease on recent heart catheterization, was found unresponsive with telemetry showing monomorphic ventricular tachycardia six hours post Carboplatin-Paclitaxel infusion. Decision-making The patient was emergently cardioverted at bedside, intubated, and started on amiodarone, lidocaine, and norepinephrine infusions. The patient was thrombocytopenic at 61K, leukopenic at 1.2K, and anemic at 7.1 with INR of 1.8. ECG showed new ST-elevation in inferior leads. Bedside echocardiogram revealed global hypokinesis with apical akinesis and a newly reduced LVEF 25%. Troponin measured 0.5 ng/mL (normal <0.04 ng/mL), creatinine 1.4, K+ 3.4, and Mg2+ 1.8. After cardio-oncology led multidisciplinary discussion, a decision was made to pursue invasive angiogram. Found to have de novo triple-vessel coronary thrombosis in mid-LAD, proximal OM1 and mid RCA (Figure 2), percutaneous intervention was performed with drug-eluting stents placed in mid-LAD and mid-RCA, with staged PCI planned on proximal OM1 if needed. Patient responded well to the intervention and was extubated the same day. Patient remained medically stable at 3-month follow-up despite continued chemotherapy. Staged PCI to OM1 was not needed.Conclusion:
Paclitaxel based therapy can cause ventricular arrhythmias and sudden cardiac death secondary to acute multi-vessel coronary thrombosis in patients without underlying coronary artery disease in the setting of pronounced thrombocytopenia. Prompt recognition of this severe adverse effect and timely utilization of multidisciplinary care models led by a cardio-oncologist achieves optimal outcomes.
amiodarone; carboplatin; creatinine; endogenous compound; lidocaine; magnesium ion; noradrenalin; paclitaxel; troponin; adverse drug reaction; aged; akinesia; anemia; blood vessel; cancer chemotherapy; cancer patient; cancer resistance; case report; clinical article; conference abstract; coronary artery atherosclerosis; coronary artery disease; coronary artery thrombosis; decision making; drug combination; drug eluting stent; drug therapy; echocardiography; electrocardiogram; electrocardiography; follow up; heart catheterization; heart left ventricle ejection fraction; heart ventricle arrhythmia; human; hyperlipidemia; hypertension; hypokinesia; international normalized ratio; male; monomorphic ventricular tachycardia; non small cell lung cancer; oncologist; outcome assessment; percutaneous coronary intervention; side effect; ST segment elevation; sudden cardiac death; telemetry; thrombocytopenia
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Journal of the American College of Cardiology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS